

PROFILE

Murray Turner, CEO, Psoriasis Australia

Murray Turner is CEO of Psoriasis Australia, a Board member of the International Alliance of Dermatological Patient Organisations (Global Skin), and a qualified lawyer.

Murray was a member of the working group that developed the “Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult Patients”, which was recently published in the *Australasian Journal of Dermatology*, and the working group developing a similar consensus statement for paediatric patients.

Before commencing his role as CEO with Psoriasis Australia, Murray worked at one of Australia’s largest law firms. After the birth of his daughter with Down Syndrome, he left the corporate world to assume the role of Executive Director for a Victorian State Sporting Organisation for athletes living with an intellectual disability, before working as a consultant to various sporting organisations, providing advice on governance and how best to include people living with a disability in programs and services.

Murray understands the needs of patients as he is also living with psoriasis, having been diagnosed with the condition at 40 years of age.

Murray is a strong supporter of clinical trials and is aware of the role they play in advancing care and scientific research. In 2009, Murray and his wife, was asked by the Neurology team at the Royal Children’s Hospital in Melbourne to participate in a world-wide study to assess the use of epileptic medications for the treatment of infantile spasms, which she had just be diagnosed with. She was the first Australian enrolment and the 55th globally. Because of this trial processes for the treatment of infantile spasms were changed.